Kyowa Hakko Kirin signs second big pharma deal for mogamulizumab
This article was originally published in Scrip
Pfizer is the second big pharma firm to team up with Kyowa Hakko Kirin to develop the latter firm's anti-CCR4 antibody mogamulizumab in a combination cancer treatment.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.